An experimental HIV vaccine increased participants’ broadly neutralizing antibody (bnAb) precursor B cells that enable the body to develop bnAb-producing B cells and fight HIV, researchers reported in study results published in December 2022. The progress comes more than a decade after researchers at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases Vaccine Research Center first discovered the rare class of antibodies.
